
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Outcomes from Kentucky Board of Pharmacy Board Authorized Protocols</title>
<style>

<style>
/* ===== GENERAL LAYOUT ===== */
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #eef2ff, #fafafa);
    color: #2c2c2c;
    padding: 30px;
    margin: 0;
}

/* Centered mindmap container */
.mindmap {
    max-width: 800px;
    margin: auto;
    font-size: 20px;
    line-height: 1.7;
}

/* ===== LISTS ===== */
.mindmap ul {
    margin: 0.6em 0 1em 1.5em;
    padding-left: 1.4em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #8b5cf6; /* accent bullet color */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}

/* ===== COLLAPSIBLE SECTIONS ===== */
.mindmap details {
    /* FIX: Increased border width and used a darker color */
    border-left: 5px solid #7c3aed; 
    background: #ffffff;
    margin: 8px 0;
    /* FIX: Corrected typo "20x" to "20px" */
    padding: 9px 25px; 
    border-radius: 20px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.1);
    transition: all 0.3s ease;
    position: relative;
}

/* Subsection (nested details) */
.mindmap details > div > details {
    margin-left: -8px;
    /* FIX: Used a darker, more saturated color for the nested border */
    border-color: #9333ea; 
    background: #faf7ff;
}

/* Subtle hover feedback */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.18);
    background: linear-gradient(135deg, #ffffff, #f5f0ff);
}

/* ===== SUMMARY HEADERS ===== */
.mindmap summary {
    cursor: pointer;
    font-size: 1.1em;
    font-weight: 600;
    list-style: none;
    position: relative;
    /* FIX: Increased padding slightly to prevent text from touching the arrow icon */
    padding-left: 24px; 
    color: #4c1d95;
    outline: none;
}

/* Custom arrow icon */
.mindmap summary::before {
    content: "â–¶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

/* Rotated arrow when open */
.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Section title emphasis */
.mindmap summary strong {
    display: block;
    font-size: 1.25em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Open section highlighting */
.mindmap details[open] > summary {
    background: #f3e8ff;
    border-radius: 8px;
    padding: 6px 10px;
}

/* Smooth fade for expanded content */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* ===== DESCRIPTION BOXES ===== */
.mindmap .desc-box {
    background: #fdfcff;
    border: 2px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 6px 10px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.05);
    transition: background 0.3s ease;
}
.mindmap .desc-box:hover {
    background: #f8f4ff;
}

/* ===== ANIMATIONS ===== */
@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}

/* ===== BUTTONS ===== */
button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
button:hover {
    background-color: #6b21a8;
    transform: scale(1.05);
}

/* ===== FLOATING CONTROL PANEL ===== */
#level-controls {
    position: fixed;
    bottom: 30px;
    left: 85%;
    transform: translateX(-50%);
    background: rgba(255, 255, 255, 0.05);
    padding: 10px 16px;
    border-radius: 12px;
    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.15);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move;
    display: flex;
    align-items: center;
    gap: 6px;
}

/* Buttons inside the panel */
#level-controls button {
    background-color: rgba(124, 58, 237, 0.85);
    color: white;
    border: none;
    padding: 8px 14px;
    font-size: 2em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s ease;
}
#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.95);
    transform: scale(1.05);
}

/* Search input inside panel */
#level-controls input {
    border: 1px solid #d5c4ff;
    border-radius: 8px;
    padding: 7px 10px;
    font-size: 0.95em;
    outline: none;
    width: 150px;
    transition: border-color 0.2s ease;
}
#level-controls input:focus {
    border-color: #8b5cf6;
}

/* Search count text */
#searchCount {
    margin-left: 8px;
    font-style: italic;
    color: #4c1d95;
    font-size: 0.9em;
}

/* ===== SEARCH HIGHLIGHT ===== */
mark.search-highlight {
    background-color: #fff59d;
    color: #000;
    border-radius: 3px;
    padding: 1px 3px;
}



/* ===== CLICK-TO-REVEAL: Spoiler Blur Style ===== */
.mindmap q {
    cursor: pointer;
    color: transparent;
    /* Apply a text-shadow with the same color as the text to create the blur effect */
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease;
}

.mindmap q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* Style for the revealed text */
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}




/*for full control button*/
/* ===== CLICK-TO-REVEAL: Spoiler Blur Style (with Read Mode) ===== */

/* This rule applies the blur ONLY when the mindmap is NOT in read-mode. */
.mindmap:not(.read-mode) q {
    cursor: pointer;
    color: transparent;
    text-shadow: 0 0 8px #2c2c2c; 
    user-select: none;
    transition: text-shadow 0.3s ease, color 0.3s ease;
}

.mindmap:not(.read-mode) q:hover {
    text-shadow: 0 0 4px #2c2c2c; /* Reduce blur on hover */
}

/* This combined rule handles BOTH cases for revealing text:
   1. The entire mindmap is in read-mode.
   2. An individual <q> has been clicked (in quiz mode).
*/
.mindmap.read-mode q,
.mindmap q.is-revealed {
    color: inherit;
    text-shadow: none;
    cursor: default;
    user-select: text;
}


</style>

</style>
</head>
<body>

<!-- Updated Controls -->
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="zoomIn()">+</button>
    <button onclick="zoomOut()">-</button>
    <button onclick="resetView()">=</button>
    <!-- NEW: READ MODE TOGGLE BUTTON -->
    <button onclick="toggleReadMode()">Q/R</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Outcomes from Kentucky Board of Pharmacy Board Authorized Protocols</strong></summary>
            <div>
                <ul><li>- Source: Study Proposal, University of Kentucky Pharmacist Care Clinic.</li><li>- Focus: Comparing outcomes for patients receiving care by pharmacists vs. traditional providers for UTIs, GAS, and COVID-19 under Board Authorized Protocols (BAPs).</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>- What are the three antibiotics approved in the UTI BAP?</li><li>- What is the age range for patients eligible for the UTI BAP?</li><li>- What is the minimum age for patients to be treated under the GAS BAP?</li><li>- What is the eGFR cutoff for severe renal impairment in the COVID-19 BAP, precluding treatment?</li><li>- What is the comparator effectiveness rate for nirmatrelvir/ritonavir used in this study?</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Introduction & Background</strong></summary>
            <div>
                <ul><li>- This study evaluates the effectiveness of expanding pharmacists' scope of practice via Board Authorized Protocols (BAPs) to address primary care shortages.</li></ul>
                
        <details>
            <summary><strong>Problem: <u>Healthcare Professional Shortage</u></strong></summary>
            <div>
                <ul><li>- <b>78 million</b> people in the U.S. live in a primary care Health Professional Shortage Area (HPSA).</li><li>- A shortage of over <q><b>13,000</b></q> healthcare professionals is projected as of May 2025.</li><li>- Kentucky alone has over <q>1,000</q> designated HPSAs.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Proposed Solution: <u>Pharmacist Scope Expansion</u></strong></summary>
            <div>
                <ul><li>- Utilize pharmacists as accessible healthcare providers, especially in rural areas.</li><li>- Kentucky's approach involves <b>Board Authorized Protocols (BAPs)</b>, allowing pharmacists to perform Point of Care Testing (POCT) and dispense specific medications without a direct contract with another provider.</li></ul>
                
        <details>
            <summary><strong>Opposition</strong></summary>
            <div>
                <ul><li>- The <b>American Medical Association (AMA)</b> has strongly opposed expanding pharmacy practice.</li><li>- Specifically opposed a bill allowing pharmacists to independently treat <q>COVID-19, influenza, RSV, and streptococcal pharyngitis</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Existing Evidence & Gaps</strong></summary>
            <div>
                <ul><li>- Data on pharmacist-led acute care outcomes is limited.</li></ul>
                
        <details>
            <summary><strong>Veterans Health Administration (VA)</strong></summary>
            <div>
                <ul><li>- Pharmacist prescribing is common, but data focuses primarily on <u>chronic conditions</u>, not acute needs.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>International Studies</strong></summary>
            <div>
                <ul><li>- <b>UTIs</b>: A Canadian study showed <u>similar clinical cure rates</u>; a UK study found no difference in time to symptom resolution.</li><li>- <b>Group A Strep (GAS)</b>: Studies mainly reviewed <u>cost-effectiveness</u> rather than clinical effectiveness.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>COVID-19 (Nirmatrelvir/Ritonavir)</strong></summary>
            <div>
                <ul><li>- Federal authority was granted to pharmacists, but practical implementation issues and restrictions limited widespread use and data collection.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Study Design & Methodology</strong></summary>
            <div>
                <ul><li>- A retrospective single cohort study design will be used.</li></ul>
                
        <details>
            <summary><strong>Hypothesis</strong></summary>
            <div>
                <ul><li>- Patients receiving care under pharmacist-driven BAPs will have <u>similar outcomes</u> compared to those receiving care from traditional providers.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Study Population</strong></summary>
            <div>
                <ul><li>- Any patient receiving testing and treatment for UTIs, GAS, and COVID-19 by a pharmacist at UK HealthCare.</li><li>- Study Period: <q>October 1, 2022</q> to <q>September 30, 2025</q>.</li><li>- A single patient may be included multiple times for separate encounters.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Data Source</strong></summary>
            <div>
                <ul><li>- Data will be extracted from the Electronic Health Record (EHR).</li><li>- Some data points will require manual chart review.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Board Authorized Protocols (BAPs): Clinical Details</strong></summary>
            <div>
                <ul><li>- Specific criteria and outcomes for each disease state managed by pharmacists.</li></ul>
                
        <details>
            <summary><strong>ðŸ’§ Uncomplicated UTI Protocol</strong></summary>
            <div>
                <ul><li>- Focuses on a narrow population of low-risk adult females.</li></ul>
                
        <details>
            <summary><strong>Inclusion Criteria</strong></summary>
            <div>
                <ul><li>- <b>Female</b>, age <q><b>18-64 years</b></q>.</li><li>- Prior history of at least one UTI.</li><li>- At least one symptom (dysuria, frequency, urgency).</li><li>- Positive POCT for <q>nitrites AND leukocytes</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Exclusion Criteria</strong></summary>
            <div>
                <ul><li>- Male, age <18 or â‰¥65, pregnant, post-menopausal.</li><li>- Symptoms of vaginitis (discharge, itching).</li><li>- Symptoms for <q>>1 week</q>.</li><li>- Immunocompromised, abnormal urinary tract structure.</li><li>- Concern for <b>pyelonephritis</b> (fever â‰¥100.4Â°F, N/V, flank pain).</li><li>- Diabetic, renal dysfunction, recent UTI/admission (<1 month), or recurrent UTIs (defined as <q>â‰¥4 per year</q>).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcomes & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Primary Outcome</b>: Rate of clinical cure, defined as <u>no repeat UTI testing/treatment</u> within <q><b>7 days</b></q> of the original POCT.</li></ul>
                
        <details>
            <summary><strong>Approved Antibiotics & Comparator Cure Rates</strong></summary>
            <div>
                <ul><li>- Comparison rates are based on literature values for similar populations.</li></ul>
                
        <details>
            <summary><strong><b>Nitrofurantoin</b></strong></summary>
            <div>
                <ul><li>- Dose: <q>100mg PO BID for 5 days</q>.</li><li>- Comparator Cure Rate: <q>79-92%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>SMX-TMP</b></strong></summary>
            <div>
                <ul><li>- Dose: <q>800-160mg PO BID for 3 days</q>.</li><li>- Comparator Cure Rate: <q>79-100%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong><b>Fosfomycin</b></strong></summary>
            <div>
                <ul><li>- Dose: <q>3gm PO once</q>.</li><li>- Comparator Cure Rate: <q>79-92%</q>.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secondary Outcomes</strong></summary>
            <div>
                <ul><li>- Time to prescription pick-up.</li><li>- Adverse events requiring follow-up within 7 days.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ðŸ¦  Group A Streptococcus (GAS) Protocol</strong></summary>
            <div>
                <ul><li>- For patients aged 5 and older with symptoms of strep throat.</li></ul>
                
        <details>
            <summary><strong>Inclusion Criteria</strong></summary>
            <div>
                <ul><li>- Age <q><b>â‰¥5 years</b></q> (parental consent required for minors).</li><li>- Symptoms consistent with GAS (sore throat, fever, swollen tonsils, etc.).</li><li>- Positive GAS POCT.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Exclusion Criteria</strong></summary>
            <div>
                <ul><li>- Age <5, pregnant/breastfeeding.</li><li>- Renal dysfunction, immunocompromised.</li><li>- History of rheumatic fever, scarlet fever, or GAS-induced glomerulonephritis.</li><li>- Antibiotic therapy within <q>1 month</q> for similar symptoms.</li><li>- <b>Clinically unstable</b>: BP <90/60, HR >125, RR >30, Temp â‰¥103Â°F.</li><li>- Concern for viral symptoms (rhinorrhea, cough, oral ulcers).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcomes & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Primary Outcome</b>: Rate of clinical cure, defined as <u>no repeat testing/treatment</u> within <q><b>7 days</b></q>.</li><li>- <b>Treatment</b>: This study arm only includes patients treated with <b>Amoxicillin</b>.</li></ul>
                
        <details>
            <summary><strong>Comparator Value</strong></summary>
            <div>
                <ul><li>- Literature on adult outcomes is sparse.</li><li>- A pediatric study will be used as a comparator, which indicates a treatment failure rate (persistent symptoms at day 6) of <q><b>4.75%</b></q> with amoxicillin.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secondary Outcomes</strong></summary>
            <div>
                <ul><li>- Time to prescription pick-up.</li><li>- Adverse events requiring follow-up within 7 days.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>ðŸ˜· COVID-19 (Nirmatrelvir/Ritonavir) Protocol</strong></summary>
            <div>
                <ul><li>- For high-risk patients with recent positive COVID-19 test.</li></ul>
                
        <details>
            <summary><strong>Inclusion Criteria</strong></summary>
            <div>
                <ul><li>- Age <q><b>â‰¥12 years</b></q> and weight <q><b>â‰¥40kg</b></q>.</li><li>- Positive SARS-CoV-2 test within <q><b>5 days</b></q>.</li><li>- At risk for hospitalization or severe disease progression.</li><li>- Ability to assess renal function, hepatic function, and drug-drug interactions.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Exclusion Criteria</strong></summary>
            <div>
                <ul><li>- Severe renal impairment (eGFR <q><b><30 ml/min</b></q>).</li><li>- Severe hepatic impairment (Child-Pugh Class C).</li><li>- Significant drug-drug interactions with potential for life-threatening reactions.</li><li>- Requiring hospital admission.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Outcomes & Treatment</strong></summary>
            <div>
                <ul><li>- <b>Primary Outcome</b>: Clinical efficacy, measured as <u>hospital admission or death</u> within <q><b>30 days</b></q> of a positive test.</li></ul>
                
        <details>
            <summary><strong>Comparator Value</strong></summary>
            <div>
                <ul><li>- An effectiveness rate of <q><b>80%</b></q> will be used for comparison.</li></ul>
                
        <details>
            <summary><strong>Supporting Literature (2022)</strong></summary>
            <div>
                <ul><li>- A US study found nirmatrelvir/ritonavir was <q><b>79.6%</b></q> effective in preventing hospitalization/death if given within 5 days of symptom onset.</li><li>- Effectiveness increased to <q><b>89.6%</b></q> if dispensed on the <u>same day</u> as testing.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Secondary Outcomes</strong></summary>
            <div>
                <ul><li>- Time to prescription pick-up.</li><li>- Adverse events requiring follow-up within 7 days.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Peer Critique & Methodological Review</strong></summary>
            <div>
                <ul><li>- This section summarizes critical feedback on the study's design, highlighting key weaknesses and suggestions for improvement.</li></ul>
                
        <details>
            <summary><strong>Overall Assessment</strong></summary>
            <div>
                <ul><li>- The research question is <b>clinically relevant and timely</b>.</li><li>- The study has high external validity for similar practice settings.</li><li>- However, its impact is limited by significant methodological weaknesses that need to be addressed.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>Major Weaknesses & Suggested Fixes</strong></summary>
            <div>
                <ul><li>- Key issues identified in the peer review that affect the validity and interpretation of the results.</li></ul>
                
        <details>
            <summary><strong>1. Inappropriate Comparator Group</strong></summary>
            <div>
                <ul><li>- <b>Weakness</b>: The plan compares outcomes to "literature values" (historical controls) instead of a local, concurrent control group. This introduces significant <u>history bias</u> and confounding.</li><li>- <b>Fix</b>: Extract a <b>contemporaneous control group</b> of patients treated by traditional providers (MD/NP) from the same health system and timeframe. Use propensity score matching or multivariable adjustment to balance covariates.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>2. Flawed Outcome Definition</strong></summary>
            <div>
                <ul><li>- <b>Weakness</b>: Defining "clinical cure" as "no repeat visit to UK HealthCare within 7 days" lacks <u>Construct Validity</u>. It risks misclassification, as patients could seek care elsewhere and be incorrectly counted as cured.</li><li>- <b>Fix</b>: Extend the follow-up window to <q>14-30 days</q>. Re-label the outcome more accurately as "Rate of re-presentation to the health system" instead of "Clinical Cure."</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>3. Incorrect Statistical Analysis</strong></summary>
            <div>
                <ul><li>- <b>Weakness</b>: The proposal to use a <b>Studentâ€™s t-test</b> for comparing proportions (e.g., cure rates) is <u>statistically incorrect</u>.</li><li>- <b>Fix</b>: Use appropriate tests for categorical data, such as <b>Chi-square</b> or <b>Fisherâ€™s exact tests</b>. For adjusted analyses, use logistic regression. For time-to-event data (COVID-19 hospitalization), use survival analysis (e.g., Cox proportional hazards models).</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>4. Selection Bias (COVID-19 Arm)</strong></summary>
            <div>
                <ul><li>- <b>Weakness</b>: Including only patients who <u>accepted and received</u> nirmatrelvir/ritonavir introduces selection bias.</li><li>- <b>Fix</b>: Ensure the comparator group is similarly defined (i.e., treated patients vs. treated patients). Adjust for potential confounders like vaccination status, comorbidities, and symptom onset timing.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>5. Vague Hypothesis Framing</strong></summary>
            <div>
                <ul><li>- <b>Weakness</b>: The hypothesis of "similar outcomes" implies a non-inferiority trial, but the study lacks a formal non-inferiority design (e.g., pre-specified margin, power analysis).</li><li>- <b>Fix</b>: Either formally design it as a non-inferiority study or rephrase the hypothesis to avoid this language and present it as a comparative effectiveness study.</li></ul>
                
            </div>
        </details>
        <br>
        
        <details>
            <summary><strong>6. Limited Generalizability (UTI Arm)</strong></summary>
            <div>
                <ul><li>- <b>Weakness</b>: The strict exclusion criteria for the UTI protocol (e.g., excluding patients >65, diabetics) reduces the external validity to populations who commonly experience UTIs.</li><li>- <b>Fix</b>: Acknowledge this limitation. Document the proportion of real-world UTI patients who would be excluded by these criteria.</li></ul>
                
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
            </div>
        </details>
        <br>
        
    </div>
    
</div>

<br>
<br>
<br>
<br>
<br>


<script>
// --- State Management for Expansion Level ---
let currentLevel = 1; 
const maxLevel = 10;
const minLevel = 1;

// --- Core Function to Set Mindmap Expansion ---
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');
    allDetails.forEach(detail => detail.removeAttribute('open'));
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') {
                depth++;
            }
            parent = parent.parentElement;
        }
        if (depth < level) {
            detail.setAttribute('open', '');
        }
    });
}

// --- Control Functions ---
function zoomIn() {
    if (currentLevel < maxLevel) {
        currentLevel++;
        setMindmapLevel(currentLevel);
    }
}

function zoomOut() {
    if (currentLevel > minLevel) {
        currentLevel--;
        setMindmapLevel(currentLevel);
    }
}

function resetView() {
    currentLevel = minLevel;
    setMindmapLevel(currentLevel);
}


// --- NEW: Function to Toggle Read/Quiz Mode ---
function toggleReadMode() {
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.classList.toggle('read-mode');
    }
}

// --- Draggable Controls ---
function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;
    const onMouseDown = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };
    const elementDrag = (e) => {
        e = e || window.event;
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none";
        elmnt.style.bottom = "auto";
    };
    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };
    if (document.getElementById(elmnt.id)) {
        document.getElementById(elmnt.id).onmousedown = onMouseDown;
    } else {
        elmnt.onmousedown = onMouseDown;
    }
}




// --- Initial Setup ---
window.addEventListener('DOMContentLoaded', () => {
    // Set the initial mindmap view
    setMindmapLevel(currentLevel);

    // Get the draggable controls element
    const controls = document.getElementById('level-controls');
    if (controls) {
        dragElement(controls);
    }

    // --- CORRECTED & IMPROVED: Setup for Click-to-Reveal ---
    const mindmapContainer = document.querySelector('.mindmap');
    if (mindmapContainer) {
        mindmapContainer.addEventListener('click', function(event) {
            // Use .closest() to find the nearest parent <q> tag.
            // This is more robust than checking event.target.tagName.
            const quoteElement = event.target.closest('q');
            
            if (quoteElement) {
                // Add the 'is-revealed' class to show the text
                quoteElement.classList.add('is-revealed');
            }
        });
    }
});
</script>

</body>
</html>
